7 completed, 2 active not recruiting, 2 recruiting, 1 enrolling by invitation. 6 Not applicable, 1 Phase 1, 1 Phase 2, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 6 | Completed 4, Enrolling by invitation 1, Recruiting 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Completed 1 |
| Phase 4 | 1 | Recruiting 1 |
Follow Type 2 Diabetes (T2D): new trials by email Literature Review of Type 2 Diabetes (T2D) trials Research Report on Type 2 Diabetes (T2D)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Metabolic Effects of Switching From Injectable Semaglutide to Tirzepatide Tirzepatide - Obesity, Type 2 Diabetes (T2D) | Active not recruiting | LMC Diabetes & Endocrinology Ltd. | 650 | 2026-10-15 | 2026-10-22 | |
| A Retrospective Real-World Cohort Study No treatment given - Obesity, Type 2 Diabetes (T2D) | Active not recruiting | Novo Nordisk A/S | 100000 | 2026-08-20 | 2026-09-30 | |
| Safety Evaluation of MODI, an Insulin Titration Algorithm, in Adults With Diabetes MODI Algorithm - Type 1 Diabetes (T1D), Type 2 Diabetes (T2D) | Not applicable | Recruiting | DreaMed Diabetes | 102 | 2026-05-25 | 2026-08-28 |
| Population Health Management for KPNC Members With Newly Diagnosed Diabetes: A Randomized Trial of a Proactive and Augmented Initial Care Strategy Augmented Initial Type 2 Diabetes Care - Type 2 Diabetes, Type 2 Diabetes Mellitus (T2DM) | Not applicable | Enrolling by invitation | Kaiser Permanente | 204 | 2025-04-01 | 2025-04-02 |
| iGlarLixi CGM Study in Chinese T2D Individuals After OADs iGlarLixi (insulin glargine/lixisenatide), Gla-100 (insulin glargine) - Type 2 Diabetes (T2D) | Phase 4 | Recruiting | Sanofi | 678 | 2024-12-10 | 2026-03-17 |
| A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes NNC0487-0111 subcutanous, Placebo (NNC0487-0111 subcutanous), NNC0487-0111 oral - Type 2 Diabetes (T2D) | Phase 2 | Completed | Novo Nordisk A/S | 448 | 2024-08-07 | 2026-10-02 |
| Liver and Metabolic Effects of Insulin Pump Therapy in Diabetics Type 2 with Non-alcoholic Hepatic Steatosis Insulin pump therapy, Multi-injection treatment ( MDI ). - Type 2 Diabetes (T2D) | Not applicable | Completed | Nantes University Hospital | 46 | 2021-02-05 | 2024-10-17 |
| Diabetes Engagement and Activation Platform Usual Care - Type 2 Diabetes (T2D) | Not applicable | Completed | Virginia Commonwealth University | 350 | 2017-11-01 | 2018-11-09 |
| NYULMC CareSmarts Pilot CareSmarts Mobile Health Diabetes Program, Standard of Care Reminders and Self Assessments - Diabetes, Type 2 Diabetes (T2D) | Not applicable | Completed | NYU Langone Health | 26 | 2016-03-01 | 2017-05-05 |
| Arsenic, Disordered Glucose Homeostasis and Atherosclerosis Atherosclerosis, Type 2 Diabetes (T2D) | Completed | NYU Langone Health | 279 | 2015-11-01 | 2020-11-13 | |
| Evaluation of Omarigliptin (MK-3102) in Obese Participants and in Participants With Type 2 Diabetes (MK-3102-004) Omarigliptin, Placebo - Type 2 Diabetes (T2D) | Phase 1 | Completed | Merck Sharp & Dohme LLC | 32 | 2010-03-11 | 2018-09-10 |
| Polyphenols and Insulin Resistance polyphenol, placebo - Healthy Volunteers, Insulin Resistance | Not applicable | Completed | University Hospital, Montpellier | 44 | 2008-10-01 | 2012-02-13 |
Diabetes Mellitus, Type 2 (12) · Insulin Resistance (2) · Obesity (2) · Atherosclerosis (1) · Cardiovascular Diseases (1) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 1 (1) · Dyslipidemias (1) · Prediabetic State (1) · Renal Insufficiency, Chronic (1)
Endocrine System Diseases (12) · Glucose Metabolism Disorders (12) · Metabolic Diseases (12) · Nutritional and Metabolic Diseases (12) · Diabetes Mellitus (11) · Body Weight (2) · Hyperinsulinism (2) · Nutrition Disorders (2) · Overnutrition (2) · Overweight (2) · Pathological Conditions, Signs and Symptoms (2) · Signs and Symptoms (2) · Arterial Occlusive Diseases (1) · Arteriosclerosis (1) · Autoimmune Diseases (1)
2-(2,5-difluorophenyl)-5-(2-(methylsulfonyl)-2,6-dihydropyrrolo(3,4-c)pyrazol-5(4H)-yl)tetrahydro-2H-pyran-3-amine (1) · Diagnostic Self Evaluation (1) · Insulin Glargine (1) · Polyphenols (1) · Tirzepatide (1) · lixisenatide (1)
NYU Langone Health (2) · Novo Nordisk A/S (2) · DreaMed Diabetes (1) · Kaiser Permanente (1) · LMC Diabetes & Endocrinology Ltd. (1) · Merck Sharp & Dohme LLC (1) · Nantes University Hospital (1) · Sanofi (1) · University Hospital, Montpellier (1) · Virginia Commonwealth University (1)
United States (6) · France (2) · Bulgaria (1) · Canada (1) · China (1) · Croatia (1) · Denmark (1) · Germany (1) · Greece (1) · Hungary (1) · Japan (1) · Poland (1) · Romania (1) · Slovakia (1) · Spain (1)
Alexander H Krist, MD (1) · Jonathan Newman, MPH (1) · Mary Sevick, MD (1)
PMID 23275372, PMID 26869191, PMID 33779567, PMID 42532079, PMID 42532080
2023 (1)